MONTREAL, March 5, 2013 /CNW Telbec/ - The Fonds de recherche du Québec - Santé (FRQS), in partnership with the Quebec Ministry of Health and Social
Services (MSSS) and the pharmaceutical company Pfizer Canada, announces
the second series of projects chosen under the Pfizer-FRQS-MSSS Chronic
Created thanks to an investment of $5 million from Pfizer Canada, this
FRQS-coordinated research grant program is aimed at evaluating and
funding chronic disease prevention and management initiatives,
fostering, where appropriate, their implementation throughout Quebec,
and making our healthcare system more efficient.
Two of the projects submitted were recommended for funding, namely,
those of the CSSS de Chicoutimi and the CSSS de l'Ouest-de-l'Île. This
announcement represents investments totalling more than $1.2 million
over the next two years.
All the projects submitted to the Pfizer-FRQS-MSSS Chronic Disease Fund
had to be in line with the Ministry of Health and Social Services'
chronic disease goals, be primary-care initiatives for promoting the
integration of chronic disease prevention and management, and focus on
changing clinical practices. In accordance with the FRQS's current
rules and procedures, the applications were examined by a scientific
review committee consisting of experts from scientific and clinical
Primary-care management of vulnerable chronic disease patients
Spearheaded by the CSSS de Chicoutimi and the CSSS Lac-Saint-Jean-Est in
Alma, the first project, named V1SAGES, is aimed at implementing and
evaluating a primary-care case-management and self-management
intervention for highly vulnerable chronic disease patients. To this
end, an intervention will be implemented in four family medicine groups
(FMGs) in Saguenay-Lac-Saint-Jean. The intervention will involve
nurse-led case management and self-management support meetings. This
project will receive a grant of $624,972 over two years.
An integrated, primary-care chronic pain prevention and management
The goal of the second project, headed by the CSSS de l'Ouest-de-l'Île,
is to implement and evaluate an integrated, primary-care chronic pain
prevention and management network. The objective is to expand an
integrated, patient-centred, interdisciplinary program for the
prevention and management of subacute low back pain in which the
intensity of the intervention is tailored to the patient's health. More
than 1200 patients will be followed on the territories of two Montreal
CSSSs (Ouest-de-l'Île, Cavendish), one CSSS in Abitibi and one in the
Montérégie. This project will receive a grant of $621,250 over two
"We're very happy to support these innovative projects, thanks to the
collaboration of MSSS and Pfizer Canada. Chronic diseases pose a
significant challenge to all of Quebec society. These unique projects,
which include both a clinical component and an evaluative research
component, are providing an opportunity to recognize and disseminate
original chronic disease prevention and management initiatives
throughout Quebec," says Dr. Renaldo Battista, Scientific Director of
the Fonds de recherche du Québec - Santé.
"Pfizer Canada is firmly committed to discovering new ways to improve
people's health and, as such, is proud to partner with the FRQS and
MSSS to stimulate innovation and the sharing of good practices and
tools created to facilitate primary care for Quebec's chronic disease
patients," notes Dr. Bernard Prigent, Vice-President and Medical
Director of Pfizer Canada.
About the Fonds de recherche du Québec - Santé (FRQS)
The mission of the Fonds de la recherche du Québec - Santé (FRQS), which reports to the Minister of Higher Education, Research, Science
and Technology, is to support health research in order to foster the
wellness of Quebecers. Its mandate is to promote and financially
support this research, to share knowledge and train researchers, as
well as to establish partnerships necessary for the development of
Quebec's research and innovation system and advance the research
internationally. For additional information visit: www.frqs.gouv.qc.ca.
About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian division of Pfizer Inc., one of the
world's leading biopharmaceutical companies. Pfizer Canada is one of
the largest contributors to health research in Canada. Pfizer's
diversified healthcare portfolio includes human and animal biologics,
small-molecule medicines and vaccines, nutritional products and many of
the world's best-known consumer products.
Every day, Pfizer Canada employees work to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our
time. We apply science and our global resources to improve the health
and well-being of Canadians at every stage of life. Our commitment is
reflected in everything Pfizer does, from our disease awareness
initiatives to our community partnerships, to our belief that it takes
more than medication to be truly healthy. To learn more about Pfizer's
More Than Medication philosophy and programs, visit morethanmedication.ca. To learn more about Pfizer Canada, visit pfizer.ca.
SOURCE: Fonds de recherche du Québec - Santé
For further information:
514-873-2114, ext. 1235